These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12773167)

  • 1. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
    Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylamine N-acetyltransferases: from structure to function.
    Sim E; Walters K; Boukouvala S
    Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arylamine N-acetyltransferases - of mice, men and microorganisms.
    Upton A; Johnson N; Sandy J; Sim E
    Trends Pharmacol Sci; 2001 Mar; 22(3):140-6. PubMed ID: 11239577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
    Sim E; Abuhammad A; Ryan A
    Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacogenetics of NAT: structural aspects.
    Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
    Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
    Sim E; Fakis G; Laurieri N; Boukouvala S
    Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
    Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
    Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid.
    Sandy J; Mushtaq A; Kawamura A; Sinclair J; Sim E; Noble M
    J Mol Biol; 2002 May; 318(4):1071-83. PubMed ID: 12054803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and mechanism of arylamine N-acetyltransferases.
    Westwood IM; Kawamura A; Fullam E; Russell AJ; Davies SG; Sim E
    Curr Top Med Chem; 2006; 6(15):1641-54. PubMed ID: 16918475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylamine N-acetyltransferases in mycobacteria.
    Sim E; Sandy J; Evangelopoulos D; Fullam E; Bhakta S; Westwood I; Krylova A; Lack N; Noble M
    Curr Drug Metab; 2008 Jul; 9(6):510-9. PubMed ID: 18680471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases.
    Brooke EW; Davies SG; Mulvaney AW; Pompeo F; Sim E; Vickers RJ
    Bioorg Med Chem; 2003 Apr; 11(7):1227-34. PubMed ID: 12628650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes.
    Sim E; Payton M; Noble M; Minchin R
    Hum Mol Genet; 2000 Oct; 9(16):2435-41. PubMed ID: 11005799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylamine N-acetyltransferases: what we learn from genes and genomes.
    Boukouvala S; Fakis G
    Drug Metab Rev; 2005; 37(3):511-64. PubMed ID: 16257833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase.
    Fullam E; Westwood IM; Anderton MC; Lowe ED; Sim E; Noble ME
    J Mol Biol; 2008 Jan; 375(1):178-91. PubMed ID: 18005984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity.
    Mushtaq A; Payton M; Sim E
    J Biol Chem; 2002 Apr; 277(14):12175-81. PubMed ID: 11799105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.
    Sandy J; Mushtaq A; Holton SJ; Schartau P; Noble ME; Sim E
    Biochem J; 2005 Aug; 390(Pt 1):115-23. PubMed ID: 15869465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity.
    Kubiak X; Dairou J; Dupret JM; Rodrigues-Lima F
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):349-62. PubMed ID: 23289949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis.
    Sandy J; Holton S; Fullam E; Sim E; Noble M
    Protein Sci; 2005 Mar; 14(3):775-82. PubMed ID: 15722451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues.
    Payton M; Mushtaq A; Yu TW; Wu LJ; Sinclair J; Sim E
    Microbiology (Reading); 2001 May; 147(Pt 5):1137-1147. PubMed ID: 11320117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylamine N-acetyltransferases.
    Sim E; Westwood I; Fullam E
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.